This article explores the emerging role of the microbiota-gut-brain axis in Alzheimer’s disease (AD), a progressive neurodegenerative disorder. Recent evidence suggests that imbalances in gut microbiota may influence AD progression through mechanisms such as neuroinflammation, immune signaling, and Aβ plaque production. While the field is still in its infancy, understanding these complex interactions could lead to microbiota-based therapies as a promising strategy for slowing or modifying AD progression.

To read the full article, click here: Current understanding of the Alzheimer’s disease-associated microbiome and therapeutic strategies | Experimental & Molecular Medicine